With no new partnerships, based on doing what we've said we're going to do, that should last us through 2011," Wolf said, adding that Sangamo expects to end 2009 with about $45 million.

The drug is an orally active nonpeptide gonadotropin-releasing hormone receptor antagonist from Neurocrine Biosciences Inc., of San Diego. (See BioWorld Today, May 7, 2009.)

MediciNova's stock (NASDAQ:MNOV) closed at $6.30, down 17 cents.

Published: August 14, 2009

Continued expression of luteinizing hormone-releasing hormone receptors in prostate cancer specimens after prolonged use of LHRH agonists supports investigating the compound in hormone-refractory prostate cancer, the company said.

Nimotuzumab is too important to be left out of the U.S."

There's a lot of work you can do between filing and approval," she noted.

auth123#Randy Osborne

auth123#Randy Osborne

We want to see how the launch goes."

But one doesn't know how these partnership ambitions can evolve."

Ltd.

He said he expects positive outcomes in all of them.

Ltd.'s buyout of MGI Pharma Inc., of Minneapolis, for $3.9 billion. (See BioWorld Today, April 11, 2008, and Dec. 11, 2007.)

has yet to name a partner for its Technosphere inhaled insulin despite success in two Phase III trials, probably largely due to the high-profile market fizzle of Exubera from Pfizer Inc., of New York. (See BioWorld Today, Dec. 5, 2008.)

Published: July 28, 2009

Given once every two weeks, albiglutide has been tried once monthly as well, but the side effects - nausea, mainly - prevented the pharma firm from proceeding at that dose.

If the earnings come to pass, Wall Street should be impressed, since estimates stand at around $4.57 per share.

The story's pretty much de-risked now."